NVAX overview

Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants.

Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza.

Gauging Analysts’ Expectations for Novavax and Peers in August

Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue. This $89.1 million grant supports Novavax’s global Phase 3 trial for pregnant women in the third trimester and licensing efforts for ResVax. Novavax has recognized ~$60 million in revenue from the BMGF grant since its inception. Previously, Novavax had grant agreements with the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority.

In this series, we’ll explore Novavax’s financial performance and significant pipeline developments along with analysts’ views on its stock.

Analysts’ recommendations

In August, of the eight analysts covering Novavax, four have given it “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “sell” rating. The mean rating for Novavax stock is 2.38, and its target price is $3.86, implying an upside potential of ~170% over its closing price of $1.43 on August 15.

Peers’ ratings

In comparison, peers AstraZeneca (AZN), GlaxoSmithKline (GSK), Merck & Co. (MRK), and AbbVie (ABBV) have mean ratings of 1.83, 2.6, 2.05, and 2.41, respectively, and target prices of $39.89, $42.19, $70.52, and $109.35, respectively.

We’ll take a look at the financial performance of Novavax in the next article.

Latest articles

21 May

Trump’s Huawei Ban Pulls Down US Chip Stocks

WRITTEN BY Scarlett Ness

Last week, Donald Trump blacklisted Chinese telecom giant Huawei Technologies amid rising US-China trade tensions.

21 May

Snap Is Making Up for Last Year

WRITTEN BY Sean Allen

This year has been a great one for Snapchat parent Snap (SNAP), and its stock has nearly doubled.

Coca-Cola (KO) will offer a limited edition of its of New Coke cans beginning May 23 as part of its partnership with Netflix’s (NFLX) show Stranger Things.

21 May

Why Clorox Stock Is Underperforming Peers

WRITTEN BY Adrian Stevens

Clorox stock (CLX) is down about 8% since the company posted its third quarter of fiscal 2019 earnings on May 1.

21 May

What JD Is Set to Get from Its Xinning Deal

WRITTEN BY Rachel Gunter

JD.com (JD) recently invested ~$55 million in purchase a ~10% stake in Jiangsu Xinning Modern Logistics, a Chinese logistics company focusing on the consumer electronics supply chain.

Today, the US stock market was on a path of recovery after starting the week on a bearish note yesterday.

172.31.1.77